Amgen is Breaking Support After 0% Profit Growth
Last qtr, Amgen (AMGN) delivered 0% profit growth as it missed analyst estimates for the first time in 3 years. Today AMGN is breaking support.
Last qtr, Amgen (AMGN) delivered 0% profit growth as it missed analyst estimates for the first time in 3 years. Today AMGN is breaking support.
Amgen’s (AMGN) expected to grow profits just 1% in 2018. And the way I see it, stock growth could likely correlate with profit growth, and I want more than 1% stock growth.
Amgen (AMGN) continues to beat the street, and could be on its way to its fifth consecutive year of double-digit profit growth. Not bad for a safe stock.
Amgen (AMGN) is down as clinical trial data for one of its big drugs wasn’t up to expectations. But AMGN still has multiple blockbusters, and a good pipeline.
Biotech stock Amgen (AMGN) has been one of the best stocks in stock market history. But what amazes me more is the company is now a refined machine.
Shares of Amgen (AMGN) are down due to volatility from the Presidential election, but the company continues to post solid profit growth.
Amgen (AMGN) is up from $150 to $174 since last quarter as investors have taken notice of this quality stock with a mid-teens P/E.
The Biotech sector is on the cusp of breaking support. Is now a good time to buy grandaddy of them all, Amgen (AMGN)?
Amgen (AMGN) management continues to underpromise then overdeliver. Last qtr the company crushed analyst estimates once again, pumping out 21% profit growth vs. estimates of 6%.
Who’s your daddy? In the Biotech space it’s Amgen (AMGN) which will be added to the Conservative Stock Portfolio.